Biosimilars Committee

IGBA member companies are the pioneers and global leaders in the development and marketing of biosimilar medicines. The objectives of the IGBA Biosimilars Committee shall be to represent, support and develop, where appropriate and necessary, the common scientific and technical interests of the biosimilar medicines industry, members of IGBA. One of the key objectives is promoting and supporting globally the scientific concept of biosimilarity.

IGBA commentary on FDA’s Draft Guidance on Labeling for Biosimilar Products

IGBA calls for full transparency and new timelines for impact assessment with regard to the voluntary WHO biological qualifier (BQ) proposal

IGBA letter to FDA regarding their biologics naming proposals

IGPA Letter Regarding TGA Guidance titled “Evaluation of Biosimilars”

Contact Info


Rue d'Arlon, 50
B-1000 Brussels, Belgium

Telephone: +32 (0)2 736 84 11
Fax: +32 (0)2 736 74 38
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.